Skip to Content

Join the 'Imlygic' group to help and get support from people like you.

Imlygic News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Colorectal Cancer, Lung Cancer, Isotretinoin, Rituxan, Claravis

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to choose the appropriate targeted therapy, said lead researcher Maria Schwaederle. Those patients also experienced nearly double the length of time before their cancer resumed growing, according to the analysis of nearly 350 clinical trials. "It is not just that the therapies are better, but that targeted therapies must be given to the right patients," said Schwaederle, who's with the University of California, San Diego School of Medicine's Center for Personalized Cancer Therapy. She will present ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Accutane, Tretinoin, Fluorouracil, Gleevec, Colorectal Cancer, Lung Cancer, Isotretinoin, Claravis, Tarceva, Skin Cancer, Xeloda, Tasigna, BCG, Revlimid, Sprycel, Hydroxyurea, Zytiga

Injected Drug Approved for Melanoma Skin Cancer

Posted 4 Nov 2015 by Drugs.com

WEDNESDAY, Oct. 28, 2015 – Imlygic (talimogene laherparepvec) has been approved by the U.S. Food and Drug Administration to treat melanoma of the skin and lymph nodes. Melanoma is the leading cause of death from skin cancer, affecting some 74,000 additional Americans annually and killing about 10,000, the FDA said in a news release. Imlygic, made from a genetically modified herpes virus, is approved to treat melanoma that cannot be completely surgically removed. It's injected directly into melanoma lesions, where it reproduces inside cancer cells and is designed to rupture and kill those cells, the agency said. The drug is to be administered every two-to-three weeks for about six months, unless other treatment is needed or there are no additional lesions to treat, the FDA said. Imlygic was evaluated in clinical studies involving more than 435 people with spreading melanoma that ... Read more

Related support groups: Melanoma, Imlygic, Talimogene Laherparepvec

New Treatment for Melanoma Gets FDA Approval

Posted 4 Nov 2015 by Drugs.com

WEDNESDAY, Oct. 28, 2015 – A genetically engineered cold sore virus that "blows up" melanoma tumors has been approved by the U.S. Food and Drug Administration to help treat the deadly skin cancer. Imlygic (talimogene laherparepvec), a first-of-its-kind therapy, showed promise against lesions in the skin and lymph nodes in an early trial, the FDA said Tuesday. However, the therapy did not improve overall survival and it did not work if the cancer had spread to other parts of the body, the agency noted. "Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat," said Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research. "This approval provides patients and health care providers with a novel treatment for melanoma." The drug is injected directly into tumors, where it replicates inside cancer ... Read more

Related support groups: Melanoma, Imlygic, Talimogene Laherparepvec

FDA Approves Imlygic (talimogene laherparepvec) for the Treatment of Melanoma

Posted 28 Oct 2015 by Drugs.com

October 27, 2015 – The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. “Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “This approval provides patients and health care providers with a novel treatment for melanoma.” Skin cancer is the most common form of cancer in the United States. Melanoma, one type of skin cancer, is the leading cause of skin cancer related deaths, and is most often caused by exposure to ultraviolet (UV) light. According to the National Cancer Institute approximately 74,000 Americans will be diagnosed with melanoma and nearly 10,000 will die from t ... Read more

Related support groups: Melanoma, Skin Cancer, Melanoma - Metastatic, Talimogene Laherparepvec, Imlygic

Ask a Question

Further Information

Related Condition Support Groups

Melanoma, Melanoma - Metastatic

Imlygic Patient Information at Drugs.com